OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Eligible age
3+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.
Sponsor: Children's Hospital Medical Center, Cincinnati
You may qualify if…
- ✓ Males or females 3 years of age and older
- ✓ Mucosal eosinophilia:
- ✓ EoE ≥ 15 eosinophils/HPF in the distal or proximal esophagus EoG ≥ 30 eosinophils/HPF in 5 HPF\'s in the body and/or antrum EoN ≥ 53 eosinophils/HPF in the duodenum and/or ≥ 56 eosinophils/HPF in the jejunum and/or ileum EoC ≥ 84 eosinophils/HPF from the transverse or descending colon and/or ≥ 32 eosinophils/HPF from the rectosigmoid colon or a biopsy from any colonic location with ≥ 100 eosinophils/HPF
- ✓ \- Presence of symptoms is required for patients who are newly diagnosed but not required for patients who were previously diagnosed.
You may not qualify if…
- ✕ History of intestinal surgery other than G tube placement
- ✕ Enrolled in a blinded investigational study at the time of the first study visit
- ✕ Have esophageal stricture (\<3mm)
- ✕ Have other identifiable causes for eosinophilia (except Inflammatory Bowel Disease): infections, Gastrointestinal (GI) cancer, other GI inflammatory disease (e.g., Ulcerative Colitis or Crohn\'s Disease)
Where it's recruiting
Phoenix
Rogers
San Diego
Aurora · Denver
Chicago
Indianapolis
Bethesda
Boston
Rochester
New York
Chapel Hill
Cincinnati
Source: ClinicalTrials.gov · NCT02523118 · last updated 2025-09-12